Diabetes is a global health problem that is caused by impaired insulin production from pancreaticβ-cells. Efforts to regenerateβ-cells have been advancing rapidly in the past two decades with progress made towards identifying new agents that induceβ-cells regeneration. ANGPTL8, also named betatrophin, has been recently identified as a hormone capable of inducingβ-cells proliferation and increasingβ-cells mass in rodents. Its discovery has been cherished as a breakthrough and a game changer in the field ofβ-cells regeneration. Initially, ANGPTL8 has been identified as atypical member of the angiopoietin-like protein family as a regulator of triglyceride in plasma through its interaction with ANGPTL3 and its regulation of lipoprotein lipase activity. In this review, we will review literature on the proposed role of ANGPTL8 inβ-cells proliferation, the controversy regarding this role, and the emerging data questioning its involvement inβ-cells proliferation. Additionally we will discuss new clinical data that describes its role in diabetes and the putative therapeutic targeting of this protein.